UP!
| 2016-05-16 | Downgrade | Leerink Swann | Outperform to Market Perform | |
| 2016-05-15 | Downgrade | Leerink Partner | Outperform to Market Perform | |
| 2016-05-15 | Downgrade | Leerink Swann | Outperform to Market Perform | |
| 2016-05-11 | Downgrade | BTIG Research | Buy to Neutral | |
| 2016-05-11 | Downgrade | Wedbush | Outperform to Neutral | $11.00 to $2.00 |
| 2016-03-16 | Lower Price Target | BTIG Research | Buy | $15.00 to $10.00 |
| 2016-03-16 | Lower Price Target | Leerink Swann | Outperform | $15.00 to $10.00 |
| 2016-03-15 | Reiterated Rating | Wedbush | Outperform | $16.00 to $11.00 |
| 2016-02-09 | Reiterated Rating | Wedbush | Outperform | $16.00 |
| 2015-11-16 | Reiterated Rating | Wedbush | Outperform | $16.00 |
| 2015-05-26 | Initiated Coverage | BTIG Research | Buy | $15.00 |
| 2015-03-25 | Boost Price Target | Leerink Swann | Outperform | $10.00 to $13.00 |
| 2015-02-18 | Initiated Coverage | Wedbush | Buy | $13.00 |
| 2014-10-06 | Initiated Coverage | Leerink Swann | Outperform | $12.00 |
| 2013-11-12 | Downgrade | Wedbush | Outperform to Neutral | $1.20 |
| 2013-11-11 | Downgrade | Oppenheimer | Outperform to Market Perform |
| 2016-05-16 | Downgrade | Leerink Swann | Outperform to Market Perform | |
| 2016-05-15 | Downgrade | Leerink Partner | Outperform to Market Perform | |
| 2016-05-15 | Downgrade | Leerink Swann | Outperform to Market Perform | |
| 2016-05-11 | Downgrade | BTIG Research | Buy to Neutral | |
| 2016-05-11 | Downgrade | Wedbush | Outperform to Neutral | $11.00 to $2.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In EPRS 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| TPG Group Holdings (SBS) Advisors, Inc. | 172.04% (22239223) | AERI / ALDR / CDNA / CZR / EPRS / FSL / GPK / IMS / LPLA / MGNX / NCLH / NTI / OTIC / PKY / Q / ROKA / SABR / SCAI / SUP / TIPT / TMHC / TNDM / VCYT / ZMH / |
| EVNIN LUKE | 86.13% (11133961) | CNAT / EPRS / EPZM / ETRM / KBIO / PCRX / PIP / RDUS / |
| MPM BIOVENTURES III LLC | 86.13% (11133961) | EPRS / PIP / RDUS / |
| 5AM Partners III, LLC | 19.72% (2549211) | BOLD / EPRS / RLYP / |
| ROCKLAGE SCOTT M | 19.72% (2549211) | AKAO / EPRS / RLYP / RTGN / |
| Gallen Christopher C. EVP, Research & Development | 14.26% (1842986) | EPRS / |
| MONTREUX EQUITY PARTNERS IV LP | 12.93% (1671400) | EPRS / |
| Snutch Terrance P. SVP & CSO | 4.66% (602603) | EPRS / |
| Renz Justin A SVP & CFO | 1.93% (250000) | EPRS / KPTI / |
| Richardson Hartley T | 1.54% (199700) | EPRS / |
| Munshi Amit Chief Executive Officer | 1.37% (177083) | ARNA / EPRS / RTGN / |
| Hunter William L | 0.85% (110022) | EPRS / |
| Wright C. Eugene | 0.37% (48280) | EPRS / |
| Wyand Michael See Remarks | 0.24% (31432) | EPRS / |
| Shea Thomas A. Chief Financial Officer | 0.23% (29970) | BIOD / EPRS / |
| CORRIGAN MARK | 0.17% (21859) | CBST / EPRS / QLTI / |
| Cole Jason Senior VP & General Counsel | 0.12% (15086) | BLUE / EPRS / |
| Ticktin Robert General Counsel | 0.03% (3949) | EPRS / |
| Vincent Aurentz Chief Business Officer | 0.02% (2200) | ARNA / EPRS / |
UM